Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijing, China.
Division of Cardiology, University of Perugia School of Medicine, Perugia, Italy.
ESC Heart Fail. 2022 Oct;9(5):3060-3070. doi: 10.1002/ehf2.14049. Epub 2022 Jun 23.
The prognostic significance of D-dimer in hospitalized heart failure (HF) patients is incompletely characterized. We aimed to assess the association of D-dimer levels on admission with adverse events at follow-up in patients hospitalized with HF across all ejection fraction (EF) phenotypes.
Consecutive patients hospitalized from December 2006 to December 2017 for HF with D-dimer and EF values available (n = 1795) were enrolled. Associations between D-dimer and all-cause death were examined at 1-year follow-up. Median age was 57 years, 73.4% were male, and the majority (72.1%) were in New York Heart Association Classes III-IV. EF was reduced in 53.3% (HFrEF), mildly reduced in 16.3% (HFmrEF), and preserved in 30.4% (HFpEF). Median (interquartile range) D-dimer on admission was 0.56 (0.27-1.295) μg/mL FEU (fibrinogen-equivalent unit) in the whole cohort, 0.64 (0.28-1.48) μg/mL FEU in HFrEF, 0.50 (0.27-1.03) μg/mL FEU in HFmrEF, and 0.495 (0.25-1.10) μg/mL FEU in HFpEF (P = 0.001). At 1-year follow-up, higher D-dimer (D-dimer ≥0.56 μg/mL FEU) independently predicted all-cause death in total cohort [hazard ratio (HR) 1.55; 95% confidence interval (CI), 1.15-2.1], in HFrEF (HR, 1.49; P = 0.039), and in HFpEF (HR, 2.06; P = 0.033). However, no relationship was found for HFrEF or HFmrEF when D-dimer was treated as quartiles. In sensitivity analysis, quantitatively similar but more pronounced association between D-dimer and all-cause death was observed in total cohort and HFpEF cohort.
In hospitalized HF patients, higher D-dimer concentration was a significant and independent predictor of 1-year all-cause mortality. Across all HF phenotypes, this effect was most evident in HFpEF patients.
在住院心力衰竭(HF)患者中,D-二聚体的预后意义尚不完全明确。本研究旨在评估所有射血分数(EF)表型的 HF 住院患者入院时 D-二聚体水平与随访期间不良事件的相关性。
连续纳入 2006 年 12 月至 2017 年 12 月期间因 HF 住院且 D-二聚体和 EF 值可用的患者(n=1795)。在 1 年随访时,研究人员评估了 D-二聚体与全因死亡之间的相关性。
中位年龄为 57 岁,73.4%为男性,大多数(72.1%)患者处于纽约心脏协会(NYHA)心功能 III-IV 级。53.3%(HFrEF)患者的 EF 值降低,16.3%(HFmrEF)患者的 EF 值轻度降低,30.4%(HFpEF)患者的 EF 值正常。整个队列中,入院时 D-二聚体的中位数(四分位距)为 0.56(0.27-1.295)μg/mL FEU(纤维蛋白原等价单位),HFrEF 中为 0.64(0.28-1.48)μg/mL FEU,HFmrEF 中为 0.50(0.27-1.03)μg/mL FEU,HFpEF 中为 0.495(0.25-1.10)μg/mL FEU(P=0.001)。在 1 年随访时,较高的 D-二聚体(D-二聚体≥0.56μg/mL FEU)在总队列中独立预测全因死亡[风险比(HR)1.55;95%置信区间(CI)1.15-2.1]、在 HFrEF 中(HR,1.49;P=0.039)和在 HFpEF 中(HR,2.06;P=0.033)。然而,当 D-二聚体作为四分位数时,在 HFrEF 或 HFmrEF 中并未发现这种关系。在敏感性分析中,在总队列和 HFpEF 队列中,D-二聚体与全因死亡之间存在定量相似但更明显的关联。
在住院 HF 患者中,较高的 D-二聚体浓度是 1 年全因死亡率的显著且独立的预测因子。在所有 HF 表型中,HFpEF 患者的这种影响最为明显。